Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, open-label single-dose study analyzing pharmacokinetics of Remdesivir and its metabolites in participants with mild to severe hepatic impairment

Next Previous
Trial Profile

A phase I, open-label single-dose study analyzing pharmacokinetics of Remdesivir and its metabolites in participants with mild to severe hepatic impairment

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remdesivir (Primary)
  • Indications COVID 2019 infections
  • Focus Pharmacokinetics; Registrational
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 19 Sep 2023 According to a Gilead Sciences media release, company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury (remdesivir) to treat people with COVID-19 with mild to severe hepatic impairment. The positive opinion was based on results from this study. Based upon these results, the revised recommendation requires no dose adjustment or liver function testing before or during treatment.
    • 24 Aug 2023 According to a Gilead Sciences media release, the approval follows recent FDA and European Commission decisions to extend approved use of Veklury to treat COVID-19 in people with severe renal impairment, including those on dialysis.
    • 24 Aug 2023 According to a Gilead Sciences media release, based on results from this study, U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury (remdesivir) with no dose adjustments to treat COVID-19 in people with mild, moderate and severe hepatic impairment.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top